Biotech Says Celgene-BMS Deal Threatens Drug Development
A biotechnology company fighting to avoid selling a psoriasis drug that's in development to Celgene, citing Bristol-Myers Squibb's $74 billion acquisition of the drugmaker and BMS' own competing treatment, invoked the...To view the full article, register now.
Already a subscriber? Click here to view full article